Laparoscopy and COVID-19 Contamination

Overview

The aim of the study is to search the presence of the SARS-COV-2 virus (COVID19) in the pneumoperitoneum of patients with a positive (or suspected) COVID19 status during a routine laparoscopy.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 1, 2022

Interventions

  • Other: Additional and minimal collection of products of the human body carried out during a sample for standard of care
    • Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice. Swab from the laparoscopy filter

Clinical Trial Outcome Measures

Primary Measures

  • The main objective of the study is to demonstrate the presence of SARS-COV-2 in the exsufflated gas at the end of laparoscopy.
    • Time Frame: Day 1 , at the end of the surgery
    • The SARS-COV-2 will be looked for in the gas before its elimination at the end of the intervention. To this end, the PCR search will be carried out on the filter used

Secondary Measures

  • The secondary objective of the study is to demonstrate the presence of SARS-COV-2 in the peritoneal fluid during laparoscopy
    • Time Frame: Day 1 , at the end of the surgery
    • SARS-COV-2 will be tested for by PCR in the peritoneal fluid collected during laparoscopy

Participating in This Clinical Trial

Inclusion Criteria

  • Patient of legal age – Indication for laparoscopy – Positive (past or current) or suspected Covid19 status (cough, fever, suggestive radiological images, etc.) – Lack of opposition to participating in the study Exclusion Criteria:

  • Patient under legal protection – Covid19 status negative, (former or current) and not suspected – Patient unable to object – Patient with no social security care

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Laura RUSCIO, +3301 45 21 34 41, laura.ruscio@aphp.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.